Kent Lake Capital’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Kent Lake Capital’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$805K	Buy	1,750,000 +563,287	+47%	+$481K	0.36%	40
2024 Q1	$1.88M	Buy	1,186,713 +101,542	+9%	+$193K	0.82%	33
2023 Q4	$2.21M	Buy	1,085,171 +901,956	+492%	+$1.56M	0.85%	36
2023 Q3	$257K	Buy	+183,215	New	+$190K	0.1%	49
2021 Q3	–	Sell	-1,053,300	Closed	-$10.5M	–	34
2021 Q2	$10.5M	Buy	1,053,300 +50,475	+5%	+$508K	4.01%	11
2021 Q1	$9.99M	Buy	1,002,825 +543,760	+118%	+$5.79M	4.06%	11
2020 Q4	$4.96M	Buy	+459,065	New	+$4.72M	2.35%	16

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

TAS

TIFF Advisory Services Radnor, Pennsylvania $408M AUM 20.34% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

Cincinnati Insurance Fairfield, Ohio $6.62B AUM 18.42% 1-Year Est. Return

BFM

Boston Financial Management Boston, Massachusetts $3.31B AUM 19.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Kent Lake Capital's STLN Position: Q2 2024 in Review

Kent Lake Capital increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 47% in Q2 2024, buying an estimated $481K and bringing the position to 1,750,000 shares worth $805K. The position accounts for 0.36% of the portfolio, ranked #40.

Kent Lake Capital first reported a position in STLN in Q4 2020 and has held it in 7 quarters since. The position peaked at $10.5M in Q2 2021. 39 funds tracked by Wall St. Rank hold STLN as of Q2 2024.

Kent Lake Capital held 1,750,000 shares of Starling Oncology Institute, Inc. Common Stock worth $805K as of Q2 2024.
Kent Lake Capital bought 563,287 Starling Oncology Institute, Inc. Common Stock shares in Q2 2024, an estimated $481K.
Starling Oncology Institute, Inc. Common Stock made up 0.36% of Kent Lake Capital's portfolio in Q2 2024, its #40 holding.
Kent Lake Capital first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2020 and has held it in 7 quarters since.
Kent Lake Capital's Starling Oncology Institute, Inc. Common Stock position peaked at $10.5M in Q2 2021.
39 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2024.

Based on Kent Lake Capital's 13F filing for Q2 2024, filed 14 Aug 2024.